Stocks and Investing
Stocks and Investing
Wed, August 10, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Gregory Renza Maintained (ADCT) at Buy with Decreased Target to $29 on, Aug 10th, 2022
Gregory Renza of RBC Capital, Maintained "ADC Therapeutics SA" (ADCT) at Buy with Decreased Target from $30 to $29 on, Aug 10th, 2022.
Gregory has made no other calls on ADCT in the last 4 months.
There are 2 other peers that have a rating on ADCT. Out of the 2 peers that are also analyzing ADCT, 0 agree with Gregory's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Gregory
- Robert Burns of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $44 on, Monday, July 11th, 2022
- Matthew Harrison of "Morgan Stanley" Maintained at Buy with Decreased Target to $17 on, Tuesday, May 10th, 2022
Contributing Sources